Wide Ranks

GERN

Geron Corporation

4.17

Top Statistics
Market Cap 2 B Forward PE -76.42 Revenue Growth 17138.40 %
Current Ratio 2.89 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -10.93 Enterprise / Revenue 76.94 Price To Sales Trailing12 Months 85.51
Profitability
Profit Margins 0.00 % Operating Margins -99.80 %
Balance Sheet
Total Cash 339 M Total Cash Per Share 0.5620 Total Debt 87 M
Total Debt To Equity 29.86 Current Ratio 2.89 Book Value Per Share 0.4850
All Measures
Short Ratio 739.00 % Message Board Id finmb_215864 Shares Short Prior Month 78 M
Return On Equity -0.6903 City Foster City Uuid c31a9eb1-93e6-345d-be75-d9dfbe5121ea
Previous Close 4.06 First Trade Date Epoch Utc 838 M Book Value 0.4850
Beta 0.5150 Total Debt 87 M Volume 6 M
Price To Book 8.60 Last Split Date 1 B Fifty Two Week Low 1.64
Total Cash Per Share 0.5620 Total Revenue 29 M Shares Short Previous Month Date 1 B
Target Median Price 7.50 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -99.80 % Target Mean Price 7.45 Net Income To Common -201192992
Short Percent Of Float 0.1167 Implied Shares Outstanding 604 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 8 M Average Volume10days 8 M
Total Cash 339 M Next Fiscal Year End 1 B Revenue Per Share 0.0470
Held Percent Insiders 0.0009 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 4.06 Target Low Price 5.50
Gmt Off Set Milliseconds -18000000 Fifty Day Average 4.19 Open 4.06
Free Cashflow -143652256 State CA Dividend Yield 0.00 %
Return On Assets -0.3030 Time Zone Short Name EST Trailing Eps -0.3200
Day Low 4.00 Address1 919 East Hillsdale Boulevard Shares Outstanding 604 M
Price Hint 4 Target High Price 10.00 Website https://www.geron.com
52 Week Change 1.16 Average Volume 8 M Forward Eps -0.0800
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 268.10 %
Last Split Factor 1058:1000 Regular Market Day High 4.21 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 29.86 Fifty Two Week High 5.34
Day High 4.21 Shares Short 70 M Regular Market Open 4.06
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 76.94
Revenue Growth 17138.40 % Shares Percent Shares Out 0.1160 Operating Cashflow -215611008
Currency USD Time Zone Full Name America/New_York Market Cap 2 B
Is_nasdaq_100 False Zip 94404 Quote Type EQUITY
Industry Biotechnology Long Name Geron Corporation Regular Market Day Low 4.00
Held Percent Institutions 0.8533 Current Price 4.17 Address2 Suite 250
Enterprise To Ebitda -10.93 Financial Currency USD Current Ratio 2.89
Gross Margins -281.22 % Industry Disp Biotechnology Number Of Analyst Opinions 10
Country United States Float Shares 557 M Two Hundred Day Average 3.93
Enterprise Value 2 B Price To Sales Trailing12 Months 85.51 Forward PE -76.42
Regular Market Volume 6 M Ebitda -207452992 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.

It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

The company was incorporated in 1990 and is headquartered in Foster City, California.